Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikas Ostwal

Showing results (11-20 of 202) with videos related to

Pageof 21
Sort By:
Nuclear Medicine Communications|October 12, 2018
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this settingAshwini Kalshetty, Anant Ramaswamy, Vikas Ostwal, et al.
South Asian Journal of Cancer|December 22, 2023
Chemotherapy-Induced Alopecia: Can We Measure the Level of Distress in Oncology Patients? (The ALDO Study)Prathepa Jagadish, Vidya Rane, Prabhat Bhargava, et al.
PET Clinics|June 21, 2016
PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine TumorsSandip Basu, Rohit Ranade, Vikas Ostwal, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|August 7, 2015
Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancersSnita Sinukumar, Shaesta Mehta, Vikas Ostwal, et al.
European Journal of Gastroenterology & Hepatology|June 4, 2016
Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspectiveDavinder Paul, Vikas Ostwal, Subhadeep Bose, et al.
Nuclear Medicine Communications|December 6, 2017
Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?Sandip Basu, Rahul V Parghane, Vikas Ostwal, et al.
Case Reports in Pathology|December 31, 2025
A Rare Case of Collision Tumor at the Periampullary RegionKshitija Kale, Vikram Chaudhari, Vikas Ostwal, et al.
Journal of Gastrointestinal Cancer|November 10, 2021
Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?Abhay K Kattepur, Shraddha Patkar, Anant Ramaswamy, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 2, 2019
Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder CancerAbhay K Kattepur, Shraddha Patkar, Mahesh Goel, et al.
Journal of Gastrointestinal Oncology|August 27, 2016
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficaciousAnant Ramaswamy, Nikhil Pande, Omshree Shetty, et al.
Pageof 21

Showing results (11-20 of 202) with videos related to

Sort By:
Pageof 21
Nuclear Medicine Communications|October 12, 2018
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this settingAshwini Kalshetty, Anant Ramaswamy, Vikas Ostwal, et al.
South Asian Journal of Cancer|December 22, 2023
Chemotherapy-Induced Alopecia: Can We Measure the Level of Distress in Oncology Patients? (The ALDO Study)Prathepa Jagadish, Vidya Rane, Prabhat Bhargava, et al.
PET Clinics|June 21, 2016
PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine TumorsSandip Basu, Rohit Ranade, Vikas Ostwal, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|August 7, 2015
Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancersSnita Sinukumar, Shaesta Mehta, Vikas Ostwal, et al.
European Journal of Gastroenterology & Hepatology|June 4, 2016
Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspectiveDavinder Paul, Vikas Ostwal, Subhadeep Bose, et al.
Nuclear Medicine Communications|December 6, 2017
Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?Sandip Basu, Rahul V Parghane, Vikas Ostwal, et al.
Case Reports in Pathology|December 31, 2025
A Rare Case of Collision Tumor at the Periampullary RegionKshitija Kale, Vikram Chaudhari, Vikas Ostwal, et al.
Journal of Gastrointestinal Cancer|November 10, 2021
Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?Abhay K Kattepur, Shraddha Patkar, Anant Ramaswamy, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 2, 2019
Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder CancerAbhay K Kattepur, Shraddha Patkar, Mahesh Goel, et al.
Journal of Gastrointestinal Oncology|August 27, 2016
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficaciousAnant Ramaswamy, Nikhil Pande, Omshree Shetty, et al.
Pageof 21